Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4328205 | 0.77 | ASH1L (0.31) | — | |
| SCHEMBL18527247 | 0.70 | DAO (0.41) | NQO2DHFRKDM4EALDH1A1MAPT | |
| SCHEMBL1752671 | 0.66 | TDP1 (0.39) | ALDH1A1 | |
| SCHEMBL18527270 | 0.65 | TDP1 (0.36) | NQO2DHFRKDM4EALDH1A1MAPT | |
| SCHEMBL12278359 | 0.64 | KDM4E (0.46) | NQO2DHFRKDM4EALDH1A1MAPT | |
| SCHEMBL4321386 | 0.64 | — | — | |
| SCHEMBL4332262 | 0.63 | DRD2 (0.35) | — | |
| SCHEMBL12043458 | 0.61 | CYP1A2 (0.31) | ALDH1A1 | |
| SCHEMBL5354038 | 0.59 | KDM4E (0.38) | NQO2DHFRKDM4EALDH1A1MAPT | |
| SCHEMBL277665 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528164-B2 | Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20060104998-A1 | Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060104998-A1 | Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, CASP4, CASP2 | NQO2 271/4885DHFR 1489/4885KDM4E 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.